Literature DB >> 19897339

A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis.

Nancy Agmon-Levin1, Yinon Shapira, Carlo Selmi, Ori Barzilai, Maya Ram, Martine Szyper-Kravitz, Sara Sella, Bat-Sheva Porat Katz, Pierre Youinou, Yves Renaudineau, Bruno Larida, Pietro Invernizzi, M Eric Gershwin, Yehuda Shoenfeld.   

Abstract

In primary biliary cirrhosis (PBC) serum markers other than anti-mitochondrial antibodies (AMA) are promising in terms of disease severity and comorbidities, as well represented by anti-nuclear antibodies (ANA). The aim of the present study was thus to evaluate the prevalence and clinical significance of a large profile of serum autoantibodies in PBC sera. We utilized 69 sera from European patients with PBC (including 20 AMA-negative) and 297 sera from geographically and sex-matched healthy controls. All sera were tested for the presence of ANA and autoantibodies associated with thrombophilia, vasculitis, and gastrointestinal disease. Autoantibodies other than AMA were detected in 53/69 (76%) PBC sera vs. 105/297 (35%) among controls. The prevalence of ANA (targeting dsDNA, Sm, chromatin, ribosomal-P, RNP, SmRNP, SSA, SSB, and centromere) and thrombophilia-associated autoantibodies (i.e. anti-beta2GPI, phosphatydilserine, prothrombin) was common among patients with PBC. When clinical features were compared, the presence of anti-prothrombin IgM was associated with a worse prognosis as represented by a higher Mayo score. We demonstrate an increased prevalence of ANA and thrombophilia-associated autoantibodies in PBC sera and an association between the latter autoantibodies and PBC stage. The role of thrombophilia-associated antibodies will warrant further studies, based in particular on the incidence of portal hypertension at early stages of PBC. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897339     DOI: 10.1016/j.jaut.2009.08.009

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  40 in total

1.  B cell depletion therapy exacerbates murine primary biliary cirrhosis.

Authors:  Amy Dhirapong; Ana Lleo; Guo-Xiang Yang; Koichi Tsuneyama; Robert Dunn; Marilyn Kehry; Thomas A Packard; John C Cambier; Fu-Tong Liu; Keith Lindor; Ross L Coppel; Aftab A Ansari; M Eric Gershwin
Journal:  Hepatology       Date:  2010-12-28       Impact factor: 17.425

2.  High frequency of antiphospholipid antibodies in primary biliary cirrhosis.

Authors:  Amani Mankaï; Wiem Manoubi; Mariam Ghozzi; Sarra Melayah; Wahiba Sakly; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

Review 3.  Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature.

Authors:  Nicola Bizzaro; Giovanni Covini; Floriano Rosina; Paolo Muratori; Elio Tonutti; Danilo Villalta; Fiorenza Pesente; Maria Grazia Alessio; Marilina Tampoia; Antonio Antico; Stefan Platzgummer; Brunetta Porcelli; Lucia Terzuoli; Marco Liguori; Danila Bassetti; Ignazio Brusca; Piero L Almasio; Giuseppe Tarantino; Chiara Bonaguri; Paolo Agostinis; Elena Bredi; Renato Tozzoli; Pietro Invernizzi; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

4.  Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis.

Authors:  L M Stinton; M Swain; R P Myers; A A Shaheen; M J Fritzler
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

Review 5.  Cutting-edge issues in primary biliary cirrhosis.

Authors:  Marco Folci; Francesca Meda; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 6.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

7.  New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays.

Authors:  Guang Song; Chaojun Hu; Heng Zhu; Li Wang; Fengchun Zhang; Yongzhe Li; Lin Wu
Journal:  J Rheumatol       Date:  2013-02-15       Impact factor: 4.666

8.  Evaluation of an automated chemiluminescent immunoassay kit for antinuclear antibodies in autoimmune diseases.

Authors:  Yaron Zafrir; Boris Gilburd; Marina Garcia Carrasco; Shaye Kivity; María Sánchez-Castañón; Marcos López-Hoyos; Mathilda Mandel; Magdalena Szmyrka; Yehuda Shoenfeld; Nancy Agmon-Levin
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 9.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

10.  The spectrum between antiphospholipid syndrome and systemic lupus erythematosus.

Authors:  Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2014-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.